Can a weekly shot ease sleep apnea without a CPAP machine?

NCT ID NCT07767942

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This phase 3 trial is testing whether an investigational drug called UBT251 can reduce the severity of obstructive sleep apnea in people who are obese and do not use positive airway pressure (PAP) therapy. Participants will receive weekly injections of UBT251 or a placebo for 52 weeks. The main goal is to see if UBT251 lowers the Apnea-Hypopnea Index (AHI), a measure of breathing pauses during sleep. The study also tracks safety and changes in body weight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
UBT251, an investigational drug given as a weekly injection
What this could lead to
If effective, UBT251 could offer a drug-based alternative to CPAP for obese individuals with moderate-to-severe sleep apnea, potentially improving breathing during sleep and reducing related health risks.
What could go wrong
This is a phase 3 trial, but results are not yet known. The drug may not significantly reduce apnea events, and side effects from the injection or the drug itself are possible. Success in this trial does not guarantee approval or effectiveness for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.